Lymphoma Clinical Trials
A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 36 clinical trials
UPCC 45418: An Open-Label Phase I/II Safety and Efficacy Study of Itacitinib in Combination with Everolimus in Subjects with Relapsed/Refractory Classical Hodgkin Lymphoma
The study will assess how safe and well-tolerated a combination of the study drugs itacitinib and everolimus in patients with Hodgkin lymphoma. We also hope to learn how effective this experimental combination is in treating Hodgkin lymphoma, when given together.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 39418: A Phase II Single Arm Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma
To evaluate the efficacy of tisagenlecleucel therapy among adult patients with refractory or relapsed follicular lymphoma as measured by complete response rate determined by Independent Review Committee in the full analysis set based on Lugano 2014 classification response criteria.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation Study to Assess the Safety Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor in Subjects with Relapsed and/or Refractory Lymphoma
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 34418: A phase Ib multicenter study to determine the safety and tolerability of tisagenlecleucel in combination with ibrutinib in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma
The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL
This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …
- 0 views
- 19 Feb, 2024
- 1 location
- 0 views
- 19 Feb, 2024
- 1 location